MX2021004022A - Modificacion genetica de enzimas dnasas para elaboracion y terapia. - Google Patents

Modificacion genetica de enzimas dnasas para elaboracion y terapia.

Info

Publication number
MX2021004022A
MX2021004022A MX2021004022A MX2021004022A MX2021004022A MX 2021004022 A MX2021004022 A MX 2021004022A MX 2021004022 A MX2021004022 A MX 2021004022A MX 2021004022 A MX2021004022 A MX 2021004022A MX 2021004022 A MX2021004022 A MX 2021004022A
Authority
MX
Mexico
Prior art keywords
dnase1
therapy
manufacturing
engineering
dnase
Prior art date
Application number
MX2021004022A
Other languages
English (en)
Inventor
Tobias A Fuchs
R Abdul Hakkim
Original Assignee
Neutrolis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutrolis Inc filed Critical Neutrolis Inc
Publication of MX2021004022A publication Critical patent/MX2021004022A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción proporciona proteínas DNASA extracelulares humanas modificadas genéticamente (por ejemplo, variantes de DNASA1 (D1), tipo DNASA1 1 (D1L1), tipo DNASA1 2 (D1L2), tipo DNASA1 3 Isoforma 1 (D1L3), tipo DNASA1 3 Isoforma 2 (D1L3-2), DNASA2A (D2A) y DNASA2B (D2B)) que son útiles para tratar afecciones caracterizadas por acumulación y/o liberación de trampa extracelular de neutrófilos (NET). De acuerdo con la invención, la variante de DNasa tiene ventajas para la terapia y/o elaboración a gran escala.
MX2021004022A 2018-10-08 2019-10-08 Modificacion genetica de enzimas dnasas para elaboracion y terapia. MX2021004022A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862742682P 2018-10-08 2018-10-08
US201862775563P 2018-12-05 2018-12-05
US201862779104P 2018-12-13 2018-12-13
US201962808601P 2019-02-21 2019-02-21
US201962846904P 2019-05-13 2019-05-13
PCT/US2019/055178 WO2020076817A1 (en) 2018-10-08 2019-10-08 Engineering of dnase enzymes for manufacturing and therapy

Publications (1)

Publication Number Publication Date
MX2021004022A true MX2021004022A (es) 2021-09-10

Family

ID=70164727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004022A MX2021004022A (es) 2018-10-08 2019-10-08 Modificacion genetica de enzimas dnasas para elaboracion y terapia.

Country Status (12)

Country Link
US (2) US11578314B2 (es)
EP (1) EP3864147A4 (es)
JP (1) JP2022504400A (es)
KR (1) KR20210072790A (es)
CN (1) CN112996911A (es)
AU (1) AU2019358915A1 (es)
BR (1) BR112021006737A2 (es)
CA (1) CA3115766A1 (es)
IL (1) IL282058A (es)
MX (1) MX2021004022A (es)
SG (1) SG11202103426XA (es)
WO (1) WO2020076817A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
AU2021288567A1 (en) * 2020-06-08 2023-02-09 Yale University Compositions and methods for treating and/or preventing coagulopathy and/or sepsis in patients suffering from bacterial and/or viral infections
US20240228995A9 (en) * 2021-02-17 2024-07-11 Neutrolis, Inc Dnase 1-like 2 engineered for manufacturing and use in therapy
WO2022246139A1 (en) * 2021-05-21 2022-11-24 Genkin Dmitry Dmitrievich Immunomodulation of tumor microenvironment

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6656685B2 (en) * 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
WO2003072741A2 (en) * 2002-02-26 2003-09-04 Southern Illinois University Therapeutic regulation of deoxyribonuclease-1-like-3 activity
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
ES2524458T3 (es) 2006-10-18 2014-12-09 Periness Ltd. DNasa para el tratamiento de la subfertilidad masculina
WO2008050104A1 (en) 2006-10-23 2008-05-02 Medical Research Council Polymerase
US8252897B2 (en) 2007-06-21 2012-08-28 Angelica Therapeutics, Inc. Modified toxins
CN113528485A (zh) * 2009-11-02 2021-10-22 华盛顿大学 治疗性核酸酶组合物和方法
US20130183662A1 (en) 2010-04-22 2013-07-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
ES2676874T3 (es) 2010-06-04 2018-07-25 Tiumbio Co., Ltd. Proteína de fusión que tiene actividad del factor VII
WO2012106264A2 (en) 2011-01-31 2012-08-09 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and gardnerella vaginalis infections
CN103732628B (zh) * 2011-03-03 2017-06-23 酵活有限公司 多价杂多聚体骨架设计和构建体
IL300276B1 (en) * 2011-04-29 2024-07-01 Univ Washington Therapeutic nuclease preparations and methods
US9642822B2 (en) 2011-05-27 2017-05-09 Children's Medical Center Corporation Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
EP3290442A1 (en) * 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
RU2642609C2 (ru) 2011-12-12 2018-01-25 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс Композиция и способ лечения болезни глаз, связанной с нуклеиновыми кислотами
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
ES2759252T3 (es) * 2013-10-31 2020-05-08 Resolve Therapeutics Llc Fusiones y métodos terapéuticos de nucleasa-albúmina
EP3110445A4 (en) 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
JP2017527618A (ja) 2014-09-08 2017-09-21 ゴッサム バイオファーマシューティカルズ，インコーポレイティド 肺サルコイドーシスの治療方法
US11047855B2 (en) 2015-03-01 2021-06-29 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
EP3273238A1 (en) 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
EP3519561A1 (en) 2016-09-30 2019-08-07 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018134419A1 (en) * 2017-01-20 2018-07-26 Universitätsklinikum Hamburg-Eppendorf Animal model for drug development
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
CN111566207A (zh) * 2017-08-18 2020-08-21 纽特雷斯股份有限公司 工程化的dna酶酶及其在疗法中的用途
US10988746B2 (en) * 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
US20220025343A1 (en) * 2019-02-04 2022-01-27 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
EA202190940A1 (ru) * 2019-05-13 2021-10-15 Ньютролис Инк. РАЗРАБОТКА ДНКаз ДЛЯ ПРОИЗВОДСТВА И ТЕРАПИИ
US20240228995A9 (en) * 2021-02-17 2024-07-11 Neutrolis, Inc Dnase 1-like 2 engineered for manufacturing and use in therapy

Also Published As

Publication number Publication date
CN112996911A (zh) 2021-06-18
AU2019358915A1 (en) 2021-05-20
CA3115766A1 (en) 2020-04-16
KR20210072790A (ko) 2021-06-17
WO2020076817A1 (en) 2020-04-16
EP3864147A4 (en) 2022-07-06
IL282058A (en) 2021-05-31
JP2022504400A (ja) 2022-01-13
BR112021006737A2 (pt) 2021-07-13
US20220162575A1 (en) 2022-05-26
SG11202103426XA (en) 2021-05-28
US11578314B2 (en) 2023-02-14
EP3864147A1 (en) 2021-08-18
US20240191218A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
MX2021004022A (es) Modificacion genetica de enzimas dnasas para elaboracion y terapia.
MX2020001913A (es) Enzimas dnasa modificadas y uso en terapia.
ZA201901924B (en) Anti¿lag¿3 antibodies and compositions
MX2023015185A (es) Degradadores de proteinas y usos de los mismos.
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MD3549592T2 (ro) Compoziții care conţin tulpini bacteriene
WO2016168592A3 (en) Compositions for modulating c9orf72 expression
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
MX2018011136A (es) Pirimidinas y variantes de estas, y usos de estas.
MX2019007784A (es) Anticuerpos humanos a la toxina hemolisina a de s. aureus.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
EA201891919A1 (ru) Способы трансфекции растений и сокращения событий случайной интеграции
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
BR112018003928A2 (pt) métodos para o tratamento de doenças
CL2021002878A1 (es) Tratamiento y prevención de enfermedades metabólicas
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2022004373A (es) Celulas madre modificadas y metodos de uso de las mismas.
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2017015147A (es) Angiogenesis usando celulas madre de placenta estimuladas.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
PH12019502578A1 (en) Methods of treatment for cervical dystonia